BioMarin Announces Record Revenues in First Quarter 2022

BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-ov...

Related Keywords

Australia ,Japan ,United States ,Slovenia ,Italy ,Czech Republic ,Saudi Arabia ,United Arab Emirates ,Canada ,American ,Debra Charlesworth ,Biomarin Aldurazyme ,Valoctocogene Roxaparvovec ,Traci Mccarty ,Jean Jacques Bienaim ,American Society Of Gene Cell Therapy ,Biomarin Pharmaceutical Inc ,Nasdaq ,Replay International Number ,Prnewswire Biomarin Pharmaceutical Inc ,Biomarin Genzyme ,Committee For Medicinal Products Human Use ,Drug Administration ,European Commission ,World Federation Of Hemophilia ,Exchange Commission ,Development Expense ,International Number ,European Medicines Agency ,Development Portfolio ,World Congress ,Total Revenues Grew ,Voxzogo Net Product Revenues Increased ,Remaining Guidance ,Severe Hemophilia ,Under Review ,Medicinal Products ,Human Use ,Opinion Anticipated Mid Year ,Biologics License Application ,Analysis Complete ,Vector Integration ,Previously Announced Adverse ,Months Ended March ,Product Revenues Marketed ,Net Product Revenues Marketed ,Marin Pharmaceutical ,Marin Announces Record Revenues ,First Quarter ,Chief Executive Officer ,Total Revenues ,Middle East ,Rare Pediatric Disease Priority Review Voucher ,Regulatory Portfolio ,Marketing Authorization Application ,American Society ,Cell Therapy ,World Federation ,Hereditary Angioedema ,Orphan Disease Designation ,Duchenne Muscular Dystrophy ,Year Financial Guidance ,Administrative Expense ,All Financial Guidance ,Canada Dial In Number ,Dial In Number ,International Dial In Number ,Biomarin Pharmaceutical ,Net Product Revenues ,Annual Report ,Nonqualified Deferred Compensation Plan ,Consolidated Financial Statements ,Asset Amortization ,Contingent Consideration ,Intangible Asset ,From Income Taxes ,Year Ending ,Guidance Year Ending December ,Based Compensation ,